Lisdexamfetamine Stats & Data

Evidence-based harm-reduction additions and clarifications: (1) Lisdexamfetamine (LDX) is a prodrug converted primarily by red blood cells to dextroamphetamine; manipulation of the dosage form or using non‑oral routes offers no pharmacological advantage and may increase harm. Red‑blood‑cell hydrolysis and PEPT1‑mediated intestinal transport underlie its smoother PK profile. (2) Food may delay Tmax by ~1 hour without meaningfully changing exposure; overall exposure and effect are more sensitive to urinary pH: acidification increases amphetamine elimination and weakens effects; alkalinization reduces elimination and can potentiate them (including with antacids). (3) Absolute contraindication with MAOIs and agents with MAOI activity (linezolid, methylene blue); risk includes hypertensive crisis and serotonin toxicity—observe 14‑day washout. (4) Concomitant SSRIs/SNRIs/TCAs are not automatically contraindicated but do raise serotonin‑toxicity and pressor risks; use of stimulants with potent CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) can elevate amphetamine exposure—monitor or avoid unsupervised combinations. (5) Additive sympathomimetic effects occur with OTC decongestants (pseudoephedrine/phenylephrine) and caffeine; even modest pseudoephedrine doses increase heart rate and slightly raise systolic BP. Avoid when possible. (6) Alcohol co‑use increases cardiovascular stress and impairs risk perception; stimulants are implicated in hypertensive crises and arrhythmias at high doses or with co‑ingestants—avoid mixing. (7) Peripheral vasculopathy (e.g., Raynaud phenomenon) has been reported during stimulant therapy; monitor for cold, numb, or discolored fingers/toes. (8) Psychiatric risks (anxiety, agitation, mania, psychosis) scale with dose/frequency; large cohort data suggest prescription stimulant–associated psychosis in ~1/660 adolescents/young adults, with amphetamines risk > methylphenidate. Stop escalation and seek care if hallucinations or delusions emerge. (9) Hydration, rest, and temperature management reduce hyperthermia and rhabdomyolysis risk during prolonged exertion on stimulants; urgent care is warranted for severe headache, chest pain, confusion, or overheating. (10) Pediatric users require growth monitoring; long‑term stimulant therapy is associated with small but measurable reductions in growth velocity. (11) Pregnancy/lactation: amphetamines cross into milk and have stimulant effects; discuss risks vs benefits with a clinician before use in these states. (12) Plan dosing timing to protect sleep (early morning dosing; avoid late‑day redosing). Insomnia worsens cardiovascular and anxiety risks. (13) Dry mouth and bruxism are common; frequent water, sugar‑free gum, and mouth care reduce dental risk. (14) Avoid polydrug stacks with additional stimulants or serotonergics; when on necessary interacting meds (e.g., SSRI), keep doses conservative and add BP/HR checks.